LactoSpore® (Heat-Stable Bacillus coagulans Probiotic)

Bacillus coagulans
Evidence Level
Moderate
1 Clinical Trial
3 Documented Benefits
3/5 Evidence Score

LactoSpore® (Sabinsa Corporation) is a spore-forming, lactic acid-producing probiotic built on one specific strain of Bacillus coagulans, MTCC 5856. Naming the strain matters, because with probiotics the strain is the product: evidence collected on one strain does not automatically apply to another. Unlike fragile Lactobacillus or Bifidobacterium species that require refrigeration and are largely destroyed by stomach acid, LactoSpore® produces heat-resistant endospores that survive manufacturing, shelf storage at room temperature, and gastric transit — germinating only when they reach the neutral-pH intestinal environment. Four randomized, placebo-controlled human trials of this exact strain are cited here, which is more strain-specific evidence than most probiotics can show. The catch is that all four were first-authored by Sabinsa's founder, so nothing has been independently replicated. Three were run in people with a diagnosed condition: diarrhea-predominant IBS, functional gas and bloating, and major depression alongside IBS, where the probiotic was added on top of existing care. That depression study is not evidence that a probiotic treats depression. The fourth looked at microbiome composition in healthy adults, and none of the four measured immune function.

Studied Dose The cited human trials used 2 billion CFU per day of Bacillus coagulans MTCC 5856, taken once daily. No cited trial tested a dose for immune support.
Active Compound Bacillus coagulans MTCC 5856 spores; heat-stable spore-forming lactic acid bacteria; minimum 2 billion CFU/g. LactoSpore by Sabinsa Corporation.

Benefits

Studied in people with IBS and in adults with gas and bloating

Two of the cited randomized, placebo-controlled trials looked at bowel symptoms. One was a 90-day pilot in 36 people diagnosed with diarrhea-predominant IBS, in which 2 billion CFU per day improved overall symptom and quality-of-life scores compared with placebo. The other tested the same strain in adults with functional gas and bloating and reported less gas and bloating than placebo. Both are studies in people who already had those problems, not evidence of what a probiotic does for someone with healthy digestion, and neither trial measured constipation. Both were small, the benefits were modest, and both were designed and funded by the company that sells the ingredient.

Spore form survives heat, shelf storage and stomach acid

LactoSpore® spores are reported by the manufacturer's own laboratory testing to tolerate heat and stomach-level acidity — enabling inclusion in beverages, baked goods, protein powders, and hot-processed foods where conventional probiotics are destroyed. Spore-forming bacteria genuinely do hold up better than the delicate Lactobacillus and Bifidobacterium strains that usually need refrigeration, which is why this strain can go into shelf-stable products and still be alive at the end. That said, the 'how much survives' numbers come from laboratory testing, not from the four human trials cited on this page, none of which counted how many organisms reached the intestine.

Gut microbiome changes measured in healthy adults

None of the four studies cited on this page measured immune function, so there is no NK cell, secretory IgA or macrophage data behind an immune claim here. What the citations do show is a microbiome effect: in a randomized, double-blind, placebo-controlled trial in healthy adults, the strain shifted gut bacteria toward groups associated with short-chain fatty acid production. That is a laboratory measurement of bacterial composition rather than a health outcome anyone would notice, and that trial, like the other three, was conducted by the manufacturer.

Mechanism of action

1

Spore germination and lactic acid production in the gut

LactoSpore® B. coagulans endospores pass through the acidic stomach intact, germinating in the neutral pH environment of the small intestine where they produce L(+)-lactic acid. The proposed mechanism is that lactic acid lowers the pH in the intestine, which may make the environment less welcoming to unwanted bacteria and more favorable to familiar Lactobacillus and Bifidobacterium species. The only human measurement of this on the page is the healthy-adult trial, which found an increase in certain beneficial Firmicutes genera linked to short-chain fatty acid production. Laboratory work suggests B. coagulans can also make substances that hold back less desirable bacteria and can interact with immune cells lining the gut, but none of this was tested in the human trials cited here, so treat it as a proposed mechanism rather than a demonstrated effect. It is also worth knowing that B. coagulans is transient: it germinates, passes through and is cleared within days, so it does not permanently settle in the gut the way the word 'colonization' suggests.

Clinical trials

1
LactoSpore® (B. coagulans MTCC 5856) for IBS — RCT
PubMed

Randomized, double-blind, placebo-controlled trial of LactoSpore® (Bacillus coagulans MTCC 5856, 2 billion CFU/day) vs placebo in 36 people diagnosed with diarrhea-predominant IBS for 90 days. Its authors describe it as a pilot study. (Majeed et al. 2016, Nutrition Journal; PMID 26922379)

36 IBS-D patients. 90-day intervention.

The strain improved overall IBS symptom and quality-of-life scores compared with placebo in this group of patients. The caveats matter: it was a small pilot in 36 people, the benefits were modest, and it was designed, funded and conducted by Sabinsa, the company that sells LactoSpore. Its first author, Muhammed Majeed, is Sabinsa's founder, and the same is true of all four human trials cited on this page, so none of the evidence here has been independently replicated. Bacillus coagulans is a spore-former — heat-stable, survives gastric acid, longer shelf life than vegetative Lactobacillus. Note: B. coagulans was previously misclassified as Lactobacillus sporogenes — that name persists in older literature but is taxonomically incorrect.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated in the cited trials, which ran up to 90 days; safety beyond that period has not been studied
Mild gas or bloating is possible in the first week or two; if it persists or worsens, stop and speak with your doctor
Immunocompromised patients — consult physician before probiotic supplementation

Important Drug interactions

Antibiotics — take LactoSpore® 2+ hours apart from antibiotic doses to reduce antibiotic suppression of probiotic
Immunosuppressants — consult physician; immune activation from probiotics may theoretically affect immunosuppression
Drug interactions have not been formally tested in the cited trials; tell your doctor or pharmacist what you are taking

Frequently asked questions about LactoSpore® (Heat-Stable Bacillus coagulans Probiotic)

What is LactoSpore?

LactoSpore® (Sabinsa Corporation) is a spore-forming, lactic acid-producing probiotic built on one specific strain of Bacillus coagulans, MTCC 5856. Naming the strain matters, because with probiotics the strain is the product: evidence collected on one strain does not automatically apply to another.

What is LactoSpore used for?

LactoSpore is researched primarily for Gut Health. Two of the cited randomized, placebo-controlled trials looked at bowel symptoms. One was a 90-day pilot in 36 people diagnosed with diarrhea-predominant IBS, in which 2 billion CFU per day improved overall symptom and quality-of-life scores…

What is the recommended dosage of LactoSpore?

The clinically studied dose is The cited human trials used 2 billion CFU per day of Bacillus coagulans MTCC 5856, taken once daily. No cited trial tested a dose for immune support. Always follow the product label and check with a healthcare provider for personal advice.

Is LactoSpore safe, and does it have side effects?

For most healthy adults, LactoSpore is well tolerated at studied doses. Reported effects can include: Generally well tolerated in the cited trials, which ran up to 90 days; safety beyond that period has not been studied Mild gas or bloating is possible in the first week or two; if it persists or worsens, stop and speak with your doctor It may also interact with some medications. LactoSpore is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does LactoSpore interact with any medications?

Possible interactions include: Antibiotics — take LactoSpore® 2+ hours apart from antibiotic doses to reduce antibiotic suppression of probiotic Immunosuppressants — consult physician; immune activation from probiotics may theoretically affect immunosuppression If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for LactoSpore?

NutraSmarts rates the evidence for LactoSpore as Moderate (3 out of 5). It is backed by 1 clinical trial and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, et al. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutrition Journal. 2016;15:21. doi: 10.1186/s12937-016-0140-6.PubMedUsed to support: Strain-specific (B. coagulans MTCC 5856 / LactoSpore) RCT reporting improved global symptom and quality-of-life scores in diarrhea-predominant IBS. Supports the IBS claim, but it is a small pilot conducted/funded by the manufacturer (Sami/Sabinsa) and benefits are modest.
  2. Majeed M, Nagabhushanam K, Arumugam S, Majeed S, Ali F Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, pilot clinical study. Food & Nutrition Research. 2018;62:1218. doi: 10.29219/fnr.v62.1218.PubMedUsed to support: Strain-specific RCT showing MTCC 5856 as an adjunct improved depression and IBS symptom scores in patients with major depression plus IBS. Backs the gut-brain/adjunct claim; small, multi-center pilot, manufacturer (Sami/Sabinsa)-conducted.
  3. Majeed M, Nagabhushanam K, Paulose S, Arumugam S, Mundkur L The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2023;102(9):e33109. doi: 10.1097/MD.0000000000033109.PubMedUsed to support: Strain-specific RCT reporting reduced functional gas and bloating with MTCC 5856 versus placebo. Supports the bowel-function/symptom claim; manufacturer (Sami/Sabinsa)-funded with modest effect sizes.
  4. Majeed M, Nagabhushanam K, Mundkur L, Paulose S, Divakar H, Rao S, et al. Probiotic modulation of gut microbiota by Bacillus coagulans MTCC 5856 in healthy subjects: A randomized, double-blind, placebo-control study. Medicine (Baltimore). 2023;102(20):e33751. doi: 10.1097/MD.0000000000033751.PubMedUsed to support: Strain-specific RCT showing MTCC 5856 favorably modulated gut microbiota (increased beneficial Firmicutes genera linked to short-chain fatty acid production) in healthy adults. Supports the mechanism behind bowel/general-gut benefits; manufacturer (Sami/Sabinsa)-conducted and a surrogate (microbiome) endpoint rather than clinical outcome.